During the last session, Ginkgo Bioworks Holdings Inc. (NYSE:DNA)’s traded shares were 20.19 million. At the end of the trading day, the stock’s price was $1.53, reflecting an intraday loss of -5.56% or -$0.09. The 52-week high for the DNA share is $4.91, that puts it down -220.92 from that peak though still a striking 26.8% gain since the share price plummeted to a 52-week low of $1.12. The company’s market capitalization is $3.10B, and the average intraday trading volume over the past 10 days was 23.58 million shares, and the average trade volume was 19.89 million shares over the past three months.

Ginkgo Bioworks Holdings Inc. (DNA) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.30. DNA has a Sell rating from 0 analyst(s) out of 9 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 4 recommend a Buy rating for it. 1 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.09.

Ginkgo Bioworks Holdings Inc. (NYSE:DNA) trade information

Ginkgo Bioworks Holdings Inc. (DNA) registered a -5.56% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -5.56% in intraday trading to $1.53 this Thursday, 05/25/23, hitting a weekly high. The stock’s 5-day price performance is 15.91%, and it has moved by 28.57% in 30 days. Based on these gigs, the overall price performance for the year is -40.70%. The short interest in Ginkgo Bioworks Holdings Inc. (NYSE:DNA) is 202.24 million shares and it means that shorts have 11.05 day(s) to cover.

The consensus price target of analysts on Wall Street is $4.46, which implies an increase of 65.7% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1.75 and $12.00 respectively. As a result, DNA is trading at a discount of -684.31% off the target high and -14.38% off the low.

Ginkgo Bioworks Holdings Inc. (DNA) estimates and forecasts

Statistics show that Ginkgo Bioworks Holdings Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Ginkgo Bioworks Holdings Inc. (DNA) shares have gone down -23.50% during the last six months, with a year-to-date growth rate more than the industry average at 66.28% against 11.40. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to grow 78.00% this quarter and then jump 80.50% in the quarter after that. In the rating firms’ projections, revenue will decrease -38.30% compared to the previous financial year.

Revenue for the current quarter is expected to be $71.81 million as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to $66.49 million by the end of Sep 2023. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $144.62 million and $66.4 million respectively. In this case, analysts expect current quarter sales to shrink by -50.30% and then jump by 0.10% in the coming quarter.

While earnings are projected to return 6.80% in 2023, the next five years will return 47.60% per annum.

DNA Dividends

Ginkgo Bioworks Holdings Inc. is due to release its next quarterly earnings on May 10. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Ginkgo Bioworks Holdings Inc. (NYSE:DNA)’s Major holders

Ginkgo Bioworks Holdings Inc. insiders own 9.21% of total outstanding shares while institutional holders control 73.73%, with the float percentage being 81.21%. Baillie Gifford and Company is the largest shareholder of the company, while 405 institutions own stock in it. As of Mar 30, 2023, the company held over 242.87 million shares (or 15.47% of all shares), a total value of $323.01 million in shares.

The next largest institutional holding, with 164.76 million shares, is of ARK Investment Management, LLC’s that is approximately 10.49% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $219.13 million.

Also, the Mutual Funds coming in first place with the largest holdings of Ginkgo Bioworks Holdings Inc. (DNA) shares are ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF. Data provided on Mar 30, 2023 indicates that ARK ETF Tr-ARK Innovation ETF owns about 106.64 million shares. This amounts to just over 6.79 percent of the company’s overall shares, with a $141.83 million market value. The same data shows that the other fund manager holds slightly less at 46.62 million, or about 2.97% of the stock, which is worth about $62.0 million.